Drug name | Tanezumab |
Phase | III |
Indication | Musculoskeletal pain and osteoarthritis |
Pharmacology description | Nerve growth factor antagonist/monoclonal antibody |
Route of administration | Injectable |
Pivotal trial(s) | [35,43] |
Pharmaprojects - copyright to Citeline Drug Intelligence (an Informa business). Readers are referred to Informa-Pipeline (http://informa-pipeline.citeline.com) and Citeline (http://informa.citeline.com).